Gliomas Clinical Trial - Chronic Convection Enhanced Delivery of Topotecan

Status Completed

Clinical Trial Summary

The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).

Clinical Trial Description

Malignant gliomas are among the most pernicious of human tumors - locally invasive and universally recurrent, with recurrence usually occurring within two centimeters of the original resection cavity. Although numerous chemotherapeutic drugs demonstrate significant anti-tumor activity in preclinical studies, the efficacy in clinical trials has been dismal because systemic delivery fails to achieve therapeutic drug levels in tumor cells due to various factors including limited blood-brain barrier permeability and systemic toxicity. Convection-enhanced delivery (CED) is a method of regional drug delivery that circumvents this problem. Phase 1 clinical trial has shown that a potent topoisomerase inhibitor, topotecan (TPT), can be safely and effectively delivered by CED into patients with recurrent malignant gliomas. This study will expand on these clinical results to address two current limitations to the clinical application of CED: 1) A reliable method for non-invasively monitoring drug distribution throughout the tumor and brain does not exist; and 2) Duration of CED therapy has been limited to short-term infusions secondary to the use of externalized infusion pumps. The hypothesis is that extended chronic local-regional delivery of TPT is safe, effective and feasible in patients with recurrent gliomas. TPT will be directly and chronically delivered into the tumor and surrounding brain by CED through subcutaneously implanted pumps while innovating a methodology for monitoring the drug distribution through non-invasive imaging. This strategy will overcome the limitations of chemotherapy as currently used in the treatment of gliomas, and may be applicable to other central nervous system (CNS) diseases currently limited by drug delivery barriers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03154996
Study type	Interventional
Source	Columbia University
Contact
Status	Completed
Phase	Phase 1
Start date	January 18, 2018
Completion date	August 20, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03952598` - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy	N/A
Not yet recruiting	`NCT01445691` - More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery	Phase 2
Terminated	`NCT01251913` - A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
Withdrawn	`NCT01961934` - C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression	Phase 2/Phase 3
Active, not recruiting	`NCT03557359` - Nivolumab for Recurrent or Progressive IDH Mutant Gliomas	Phase 2
Recruiting	`NCT01655927` - Efficacy of Tranexamic Acid in Brain Tumor Resections	Phase 3
Completed	`NCT01144247` - Cellular Immunotherapy Study for Brain Cancer	Phase 1
Completed	`NCT01225003` - Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas	N/A
Completed	`NCT00967577` - 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors	Phase 1
Terminated	`NCT01517776` - Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents	Phase 2
Completed	`NCT00832598` - [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors	N/A
Completed	`NCT00589706` - A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas	Phase 2
Withdrawn	`NCT05054400` - Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR	Early Phase 1
Recruiting	`NCT03091270` - ZOOMit-fMRI Identifies Motor Functional Cortex
Completed	`NCT00200161` - Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma	Phase 2
Terminated	`NCT02332889` - Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs	Phase 1/Phase 2
Recruiting	`NCT05804227` - Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults	Early Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.